Standout Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma 2005 2026 2012 2019 4.4k
  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma (2007)
    Robert J. Motzer, Thomas E. Hutson et al. New England Journal of Medicine
  2. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009)
    Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology
  3. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma (2005)
    Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology
  4. Sunitinib in Patients With Metastatic Renal Cell Carcinoma (2006)
    Robert J. Motzer, Brian I. Rini et al. JAMA
  5. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (2015)
    Robert J. Motzer, Thomas E. Hutson et al. The Lancet Oncology
  6. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (2013)
    Robert J. Motzer, Bernard Escudier et al. The Lancet Oncology
  7. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (2017)
    Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology
  8. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience (2017)
    Nicholas J. Giacalone, William U. Shipley et al. European Urology

Immediate Impact

13 by Nobel laureates 7 from Science/Nature 114 standout
Sub-graph 1 of 18

Citing Papers

Renal cell carcinoma
2024 Standout
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
78 intermediate papers

Works of M. Dror Michaelson being referenced

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
2017 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
and 41 more

Author Peers

Author Last Decade Papers Cites
M. Dror Michaelson 12062 6031 5898 9235 213 16.8k
Georg A. Bjarnason 7795 4391 4441 6569 273 13.5k
Cezary Szczylik 15634 7987 8379 13906 318 23.4k
Sylvie Négrier 13333 8329 6757 10907 225 20.5k
Alain Ravaud 10175 6677 4762 7878 366 17.4k
Thomas E. Hutson 17554 8223 9081 14661 286 24.4k
Laurence Albigès 10230 4944 4028 6270 448 13.7k
Tim Eisen 6902 4331 4084 7341 145 12.6k
Sergio Bracarda 7422 4285 3707 5689 230 11.3k
Christine Chevreau 9987 6054 3788 6252 308 15.3k
Christian Kollmannsberger 8462 4710 3314 5383 381 13.6k

All Works

Loading papers...

Rankless by CCL
2026